April 26th 2024
Melton, customer advocacy executive at Magnolia, discusses how new technologies can be used to ensure data is accurate.
Bristol Myers Squibb Reveals Promising Data for KarXT, a Potential Treatment for Schizophrenia
April 9th 2024A combination of data from the EMERGENT-4 trial and pooled data from the EMERGENT program showed the promise of KarXT (xanomeline-trospium) in providing symptom improvement for people with schizophrenia.
Navigating the CBD Research Landscape: Unveiling Best Practices in the Post-MMCREA Era
March 14th 2024Although research on cannabinoids is now allowed in a growing number of countries, there are still a number of restrictions and corresponding licenses and permits required to work with these chemicals.
What's Causing the Slowdowns in Trial Starts?
March 5th 2024In this Pharmaceutical Executive video interview, Murray Aitken, Executive Director of the IQVIA Institute for Human Data Science, discusses findings from IQVIA's Global Trends in R&D 2024 report and what specific factors are causing this slowdown in clinical trial starts.